A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

NCT02423902 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
9
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.

Conditions

Interventions

Sponsor

Alaunos Therapeutics